Scholar Rock Holding Corp
A biopharmaceutical company in Cambridge, Massachusetts that develops antibody medicines for muscle-wasting diseases. Its lead therapy, apitegromab, targets a protein that limits muscle growth and is being tested for spinal muscular atrophy. Founded in 2012 by Harvard Medical School researchers, the company takes its name from Chinese "scholar's rocks"—eroded stones prized for sparking insight—because their rugged shapes resemble the protein structures it studies.
Granted 28.0K · Bought 2.72M · Sold 1.18M
Bought 2.51M · Sold 1.1K
Sold 2.01M
Bought 2.19M
Bought 1.34M
Bought 71.4K
Granted 117.8K · Sold 5.4K
Bought 450.0K
Granted 1.64M · Sold 88.1K
Granted 100.0K
Granted 660.5K · Sold 39.4K
Granted 647.0K · Sold 27.0K
Granted 647.0K · Sold 27.2K
Granted 477.9K · Sold 52.3K
Bought 142.9K
Granted 53.3K
Granted 265.0K · Sold 52.2K
Granted 182.6K · Sold 49.4K
Granted 93.1K · Sold 22.7K
Granted 261.6K · Sold 135.6K
Granted 667.4K · Sold 577.6K
Granted 338.4K · Sold 339.0K
Granted 13.6K · Sold 13.6K
Granted 117.1K · Sold 45.4K
Granted 31.5K · Sold 13.4K
Granted 48.3K · Sold 61.2K
Granted 42.0K
Granted 45.8K · Sold 6.0K
Granted 28.0K · Sold 5.4K
Granted 28.0K · Sold 6.1K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Akkaraju SrinivasDirector · 17 transactions | — | 12.23M | 28.0K | 2.72M | 1.18M |
| Artal Group S.A. +7 co-filers10% owner · 8 transactions | — | 11.26Mas of Oct 2023 | — | 2.51M | 1.1K |
| Debbane Raymond +2 co-filers10% owner · 1 transaction | — | 10.83M | — | — | — |
| Debbane Raymond +4 co-filers10% owner · 6 transactions | — | 9.25Mas of Dec 2024 | — | — | 2.01M |
| Samsara BioCapital GP, LLC +1 co-filer10% owner · 1 transaction | — | 6.79Mas of Oct 2023 | — | 2.19M | — |
| Nashat AmirDirector · 53 transactions | — | 6.24Mas of May 2024 | — | 1.34M | — |
| Springer Timothy A10% owner · 9 transactions | — | 6.21Mas of Dec 2019 | — | 71.4K | — |
| Burow KristinaDirector · 16 transactions | — | 4.81M | 117.8K | — | 5.4K |
| Artal Group S.A. +7 co-filers10% owner · 2 transactions | — | 2.40Mas of May 2018 | — | 450.0K | — |
| Hallal DavidChief Executive Officer, Director · 8 transactions | — | 1.84M | 1.64M | — | 88.1K |
| Bybee Clinton +5 co-filers10% owner · 5 transactions | — | 1.62Mas of May 2018 | — | — | — |
| Mahanthappa Nagesh K.Interim CEO and President · 2 transactions | — | 861.0Kas of Jun 2022 | 100.0K | — | — |
| Vaishnaw AkshayPresident of R&D, Director · 8 transactions | — | 630.5K | 660.5K | — | 39.4K |
| Woods KeithChief Operating Officer · 5 transactions | — | 620.1K | 647.0K | — | 27.0K |
| Sinha VikasChief Financial Officer · 5 transactions | — | 619.9K | 647.0K | — | 27.2K |
| Backstrom Jay T.CHIEF EXECUTIVE OFFICER, Director · 6 transactions | — | 425.6Kas of Mar 2025 | 477.9K | — | 52.3K |
| Polaris Venture Management Co. VI, L.L.C. +2 co-filers10% owner · 14 transactions | — | 350.3Kas of May 2018 | — | 142.9K | — |
| Chyung Yung H.Chief Medical Officer · 3 transactions | — | 258.5Kas of Feb 2022 | 53.3K | — | — |
| Ho JunlinGENERAL COUNSEL · 18 transactions | — | 241.5K | 265.0K | — | 52.2K |
| Parlavecchio CarynCHRO · 19 transactions | — | 169.1K | 182.6K | — | 49.4K |
| Carven Gregory JohnChief Scientific Officer · 9 transactions | — | 128.2Kas of Jun 2022 | 93.1K | — | 22.7K |
| Marantz Jing L.CHIEF MEDICAL OFFICER · 19 transactions | — | 126.0K | 261.6K | — | 135.6K |
| Myles Edward HCOO & CFO · 39 transactions | — | 111.3Kas of Mar 2025 | 667.4K | — | 577.6K |
| Qatanani MoCHIEF SCIENTIFIC OFFICER · 44 transactions | — | 98.6K | 338.4K | — | 339.0K |
| Moore ErinInterim PFO and PAO · 3 transactions | — | 96.2Kas of Mar 2025 | 13.6K | — | 13.6K |
| Sacco TraceyChief Commercial Officer · 12 transactions | — | 76.3Kas of Apr 2025 | 117.1K | — | 45.4K |
| Gilman MichaelDirector · 16 transactions | — | 62.1K | 31.5K | — | 13.4K |
| Flier Jeffrey S.Director · 16 transactions | — | 42.0K | 48.3K | — | 61.2K |
| Kingsley Stuart APresident and CEO, Director · 1 transaction | — | 42.0Kas of Feb 2021 | 42.0K | — | — |
| Peng KatieDirector · 11 transactions | — | 39.7K | 45.8K | — | 6.0K |
| Reed JoshuaDirector · 5 transactions | — | 22.6K | 28.0K | — | 5.4K |
| Brudnick RichardDirector · 5 transactions | — | 21.9K | 28.0K | — | 6.1K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: +4.67M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.